Adrenal Steroidogenesis in Methylandrostenediol-Induced Hypertension*
- 1 July 1978
- journal article
- research article
- Published by The Endocrine Society in Endocrinology
- Vol. 103 (1) , 1-5
- https://doi.org/10.1210/endo-103-1-1
Abstract
Adrenal vein catheterizations were done in rats made hypertensive by administration of methylandrostenediol (MAD; 17.alpha.-methyl-5-androstene-3.beta.,-17.beta.-diol), and in control rats at intervals during treatment. All MAD-treated rats were hypertensive by 7 wk. Secretion of corticosterone was consistently decreased at all times in MAD-treated rats. 18-Hydroxy-11-deoxycorticosterone secretion and 11-deoxycorticosterone (DOC) secretion decreased and increased, respectively, compared to controls at 2, 4 and 6 wk. Aldosterone secretion was decreased at 2 and 4 wk. This study shows an in vivo block of adrenal 11- and 18-hydroxylation. Transient DOC accumulation by treatment with MAD produced hypertension, though DOC oversecretion and other changes in steroidogenesis were waning by the time hypertension developed.This publication has 7 references indexed in Scilit:
- Radioimmunoassay of 18-hydroxy-ll-deoxycorticosterone in PlasmaJournal of Clinical Endocrinology & Metabolism, 1976
- Adrenal plasma levels of corticosterone and deoxycorticosterone in methylandrostenediol-salt induced hypertension (1)Steroids, 1968
- Metabolism of 17α-Methylandrostenediol and 17α-Methyltestosterone by the Rat Adrenal Glandin VitroEndocrinology, 1967
- Method forin Vivo cannulation of both adrenal glands of the hamsterThe Anatomical Record, 1961
- PATHOLOGIC CHANGES IN SENSITIZED RATS TREATED WITH METHYLANDROSTENEDIOL AND WITH GROWTH HORMONE1Endocrinology, 1958
- THE PRODUCTION OF HYPERTENSION, NEPHROSCLEROSIS AND CARDIAC LESIONS BY METHYLANDROSTENEDIOL TREATMENT IN THE RAT1Endocrinology, 1954
- THE PRODUCTION OF HYPERTENSION, NEPHROSCLEROSIS AND CARDIAC LESIONS BY METHYLANDROSTENEDIOL TREATMENT IN THE RAT1Endocrinology, 1953